Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2024
Reporting Period: Single event date (February 28, 2024)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing discloses a strategic partnership regarding clinical research.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Strategic Partnership: On February 28, 2024, the Company announced a partnership with Cliantha Research, a full-service Clinical Research Organization (CRO).
Objective: The partnership is to perform a pharmacokinetic (PK) study.
Regulatory Context: This study forms part of the Company's FDA 510(k) clinical study plan.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for full details regarding the partnership and study plan.
Legal Disclaimer: The information disclosed under Item 7.01 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, except as expressly set forth by specific reference.
Risks: No specific risks or contingencies are detailed within the text of this 8-K summary; investors are directed to the full press release for qualifications.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) for specific terms of the partnership with Cliantha Research.
- Confirm the timeline and scope of the pharmacokinetic (PK) study within the FDA 510(k) plan.
- Review the Company's most recent 10-K or 10-Q filings for current financial health, as this 8-K contains no financial data.
- Monitor future filings for updates on the clinical study results and regulatory progress.